Vanda Pharmaceuticals financials
$5.03−2.71%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $216.1M | $198.8M | $192.6M | $254.4M | $268.7M | $248.2M | $227.2M | $193.1M | $165.1M | $146.0M |
| Gross profit | $203.1M | $187.5M | $177.8M | $230.1M | $243.1M | $224.8M | $202.7M | $172.6M | $147.2M | $121.3M |
| Gross margin | 94.0% | 94.3% | 92.3% | 90.5% | 90.5% | 90.6% | 89.2% | 89.4% | 89.2% | 83.1% |
| Operating income | -$151.2M | -$40.7M | -$14.0M | $6.3M | $42.2M | $27.2M | $22.8M | $21.7M | -$16.9M | -$18.6M |
| Net income | -$220.5M | -$18.9M | $2.5M | $6.3M | $33.2M | $23.3M | $115.6M | $25.2M | -$15.6M | -$18.0M |
| Net margin | −102.0% | −9.5% | 1.3% | 2.5% | 12.3% | 9.4% | 50.9% | 13.1% | −9.4% | −12.3% |
| Diluted EPS | $-3.74 | $-0.33 | $0.04 | $0.11 | $0.58 | $0.42 | $2.11 | $0.48 | $-0.35 | $-0.41 |
| EBITDA | -$143.1M | -$32.5M | -$10.9M | $9.1M | $45.0M | $30.1M | $25.7M | $24.7M | -$13.9M | -$6.7M |
| Operating cash flow | -$109.4M | -$15.8M | $12.8M | $32.0M | $64.2M | $51.8M | $45.9M | $30.0M | -$2.0M | -$8.1M |
| Free cash flow | -$110.4M | -$16.2M | $12.4M | $31.3M | $63.7M | $50.0M | $44.9M | $29.6M | -$3.6M | -$9.5M |
| Diluted shares | 58.9M | 58.1M | 57.6M | 57.0M | 56.9M | 55.2M | 54.8M | 53.0M | 44.7M | 43.4M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $84.9M | $102.3M | $135.8M | $135.0M | $52.1M | $61.0M |
| Short-term investments | $179.0M | $272.3M | $252.4M | $331.8M | $380.7M | $306.7M |
| Total debt | $4.1M | $3.1M | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $488.9M | $656.2M | $648.4M | $634.2M | $593.8M | $533.5M |
| Total liabilities | $161.8M | $117.7M | $103.5M | $107.0M | $88.9M | $80.2M |
| Shareholders' equity | $327.2M | $538.5M | $544.9M | $527.2M | $504.9M | $453.3M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology